World Autism Awareness Day Webinar 2023
Meet Our Speakers
Dr. James Brasic
Section of High Resolution Brain Positron Emission Tomography Imaging, Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, USA, Section Board Member of Brain Sciences (ISSN: 2076-3425), Guest Editor of IJMS ( ISSN: 1422-0067);
Dr. James Brasic is a neurologist and child and adolescent psychiatrist who conducts clinical translational investigations of autism spectrum disorder and other neuropsychiatric conditions. As an assistant professor of radiology and radiological science and neurology at the Johns Hopkins University School of Medicine in Baltimore, Maryland, United States of America, he utilizes positron emission tomography (PET) and other multimodal techniques to improve the diagnosis and treatment of subtypes of autism spectrum disorder (idiopathic autism spectrum disorder and fragile X and Rett syndromes) and other nervous and mental disorders. He is leading international teams to the investigate the pathophysiology of autism spectrum disorder and other neurodevelopmental disabilities as well as Parkinson’s disease and related conditions. He welcomes opportunities for collaboration with colleagues around the world on studies to diagnose, treat, cure, and ultimately prevent autism spectrum disorder and other neurodevelopmental and neurodegenerative disorders. He will deliver a prepared speech entitled “Developing a relaxation response to catastrophes.”
Dr. Kazuhito Toyooka
Department of Neurobiology and Anatomy, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, PA 19129, USA, Section Board Member of Brain Sciences (ISSN: 2076-3425), Guest Editor of IJMS (ISSN: 1422-0067);
Dr. Toyooka is an assistant professor in the Department of Neurobiology and Anatomy at Drexel University College of Medicine. After completing his doctoral studies at Osaka University, Japan, he completed postdoctoral fellowships at the University of California San Diego and the University of California San Francisco. Additionally, he was a faculty member at Osaka City University School of Medicine in Japan. Since 2013, he has been a faculty member in the Department of Neurobiology and Anatomy of Drexel University College of Medicine.
Dr. Richard Boles
Medical Geneticist, Mitochondrial and Molecular Medicine, 630 S Raymond Ave, Unit 310, Pasadena, CA 91105, USA, Director of the NeuroGenomics Program at NeurAbilities, Chief Medical & Scientific Officer of NeuroNeeds, Section Board Member of JPM (ISSN: 2075-4426);
Dr. Boles is a Medical Geneticist with expertise in mitochondrial, other metabolic disorders, and channelopathies. He completed medical school at UCLA, a pediatric residency at Harbor-UCLA, and a genetics fellowship at Yale. Dr. Boles’ clinical and research focus has been on the genetics of common neurological disorders, including autism, ADHD, chronic pain, fatigue, and cyclic vomiting. He has over 90 published papers. Dr. Boles was the Medical Director of a DNA sequencing laboratory for 6 years. He currently is the Director of the NeuroGenomics Program at NeurAbilities, where he applies whole DNA sequencing to determine the cause of disease in his patients. Dr. Boles is also the Chief Medical & Scientific Officer of NeuroNeeds, a company that produces natural nutritional products to assist people with neurological conditions, including autism and other conditions listed above.
Dr. Richard E. Frye
Autism Discovery and Treatment Foundation, Phoenix AZ, Editorial Board Member of JPM (ISSN: 2075-4426);
Dr Frye is a Child Neurologist with expertise in neurodevelopmental and neurometabolic disorders. He received an MD and PhD in Physiology and Biophysics from Georgetown University. He completed a residency in Pediatrics at the University of Miami, Residency in Child Neurology and Fellowship in Behavioral Neurology and Learning Disabilities at Harvard University/Children’s Hospital Boston and Fellowship in Psychology at Boston University. He also received a Masters in Biomedical Science and Biostatistics from Drexel University. He holds board certifications in Pediatrics, and in Neurology with Special Competence in Child Neurology. He has authored over 300 publications and book chapters and serves on several editorial boards and is the former Editor-in-Chief for the Section on Mechanisms of Diseases of the Journal of Personalized Medicine.
Dr. Frye is a national leader in autism spectrum disorder (ASD) research. He has lead several clinical studies on children with ASD, including studies focusing on defining the clinical, behavioral, cognitive, genetic and metabolic characteristics of children with ASD and mitochondrial disease and several clinical trials demonstrating the efficacy of safe and novel treatments that target underlying physiological abnormalities in children with ASD, including open-label studies on tetrahydrobiopterin, cobalamin and leucovorin and a recent double-blind placebo controlled trial on leucovorin. His ongoing research efforts focus on defining metabolic endophenotypes of children with ASD and developing targeted treatments.
In order to commemorate World Autism Awareness Day 2023 (https://www.un.org/en/observances/autism-day), MDPI is launching a special webinar to encourage researchers to join together, take action, and raise awareness as to how the exchange of findings facilitates efforts to raise awareness about autism.
Over the past decade, major progress has been made towards increasing access to education generally, as well as for persons with autism specifically.
The webinar aims to encourage connection and collaboration among autism researchers and the international open access community to help improved the life of autistic people.
We are very much looking forward to seeing you at the World Autism Awareness Day 2023. Please find below an up-to-date outline of invited speakers.
Conference Secretariat
Ms Shun Li